Speech treatment for Parkinson's disease

Expert Review of Neurotherapeutics

Volumn 8, Issue 2, 2008, Pages 297-309

  Ramig, Lorraine O ^a,b,c   Fox, Cynthia ^d,e   Sapir, Shimon ^f  

^a UNIVERSITY OF COLORADO   (United States)

^b Denver Center for the Performing Arts   (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

^d University of Arizona   (United States)

^e UNIVERSITY OF ARIZONA   (United States)

^f UNIVERSITY OF HAIFA   (Israel)

Author keywords

Dysarthria; Hypokinetic; Hypophonia; LSVT ; Neural plasticity; Parkinson's disease; Speech and voice disorder; Speech and voice treatment

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA;

BRAIN DEPTH STIMULATION; BRAIN INJURY; DISEASE ASSOCIATION; DISEASE COURSE; DYSARTHRIA; HUMAN; LARYNX DISORDER; MOTOR PERFORMANCE; NERVE CELL PLASTICITY; NEUROPATHOLOGY; PALLIDOTOMY; PARKINSON DISEASE; REVIEW; SPEECH; SPEECH DISORDER; SPEECH THERAPY; THALAMOTOMY;

HUMANS; PARKINSON DISEASE; SPEECH; SPEECH THERAPY; VOICE DISORDERS;

EID: 39549084554     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.8.2.297     Document Type: Review

References (153)

1. Hartelius L, Svensson P. Speech and swallowing symptoms associated with Parkinson's disease and multiple sclerosis: a survey. Folia Phoniatr. Logop. 46, 9-17 (1994).
2. Ho AK, Iansek R, Marigliani C, Bradshaw JL, Gates S. Speech impairment in a large sample of people with Parkinson's disease. Behav. Neurol. 11, 131-137 (1998).
3. Logemann J, Fisher H, Boshes B, Blonsky E. Frequency and concurrence of vocal tract dysfunctions in the speech of a large sample of Parkinson people. J. Speech Hear. Disord. 43, 47-57 (1978).
4. Pitcairn T, Clemie S, Gray J, Pentland B. Non-verbal cues in the self presentation of parkinsonian people. Br. J. Clin. Psychol. 29, 177-184 (1990).
5. Pitcairn T, Clemie S, Gray J, Pentland B. Impressions of parkinsonian people from their recorded voices. Br. J. Clin. Psychol. 25, 85-92 (1990).
6. Fox C, Ramig L. Vocal sound pressure level and self-perception of speech and voice in men and women with idiopathic Parkinson disease. Am. J. Speech. Lang. Pathol. 2, 29-42 (1997).
7. Miller N, Noble E, Jones D, Burn D. Life with communication changes in Parkinson's disease. Age Ageing 35(3), 235-239 (2006).
8. D'Amelio M, Ragonese P, Morgante L et al. Long-term survival of Parkinson's disease: a population-based study. J. Neurol. 253, 33-37 (2006).
9. Schenkman M, Zhu CW, Cutson TM, Whetten-Goldstein K. Longitudinal evaluation of economic and physical impact of Parkinson's disease. Parkinsonism Relat. Disord. 2, 41-50 (2001).
10. Wermuth L, Stenager EN, Stenager E, Boldsen J. Mortality in patients with Parkinson's disease. Acta. Neurol. Scand. 92, 55-58 (1995).
11. Whetten-Goldstein K, Sloan F, Kulad E, Cutson T, Schenkman M. The burden of Parkinson's disease on society, family, and the individual. J. Am. Geriatr. Soc. 45, 844-849 (1997).
12. Noyes K, Lui H, Li H, Holloway R, Dick AW. Economic burden associated with Parkinson's disease on elderly Medicare beneficiaries. Mov. Disord. 3, 362-372 (2006).
13. Huse DM, Schulman K, Orsini L, Castelli-Haley J, Kennedy S, Lenhart G. Burden of illness in Parkinson's disease. Mov. Disord. 20, 1449-1454 (2005).
14. Baker K, Ramig LO, Johnson A, Freed C. Preliminary speech and voice analysis following fetal dopamine transplants in 5 people with Parkinson disease. J. Speech Hear. Res. 20(3), 615-626 (1997).
15. Ghika J, Ghika-Schmid F, Fankhauser H et al. Bilateral contemporaneous posteroventral pallidotomy for the treatment of Parkinson's disease: neuropsychological and neurological side effects, report of four cases and review of the literature. J. Neurosurg. 9(2), 313-321 (1999).
16. Kompoliti K, Wang QE, Goetz CG, Leurgans S, Raman R. Effects of central dopaminergic stimulation by apomorphine on speech in Parkinson's disease. Neurology 54, 458-462 (2000).
17. Larson K, Ramig LO, Scherer RC. Acoustic and glottographic voice analysis during drug-related fluctuations in Parkinson's disease. J. Med. Speech Lang. Pathol. 2, 211-226 (1994).
18. Rigrodsky S, Morrison EB. Speech changes in parkinsonism during L-dopa therapy: preliminary findings. J. Am. Geriatr. Soc. 18, 142-151 (1970).
19. Wang E, Kompoliti K, Jiang J, Goetz CG. An instrumental analysis of laryngeal responses to apomorphine stimulation in Parkinson disease. J. Med. Speech Lang. Pathol. 8, 175-186 (2002).
20. Wolfe VI, Garvin JS, Bacon M, Waldrop W. Speech changes in Parkinson's disease during treatment with L-dopa. J. Commun. Disord. 8(3), 271-279 (1975).
21. Allan CM. Treatment of non-fluent speech resulting from neurological disease: treatment of dysarthria. Br. J. Disord. Commun. 5, 3-5 (1970).
22. Clinical Voice Disorders. Aronson AE (Ed.). Thieme-Stratton, NY, USA (1990).
23. The Voice and Its Disorders. Greene HCL (Ed.). Pitman Medical, London, UK (1980).
24. Sarno MT. Speech impairment in Parkinson's disease. Arch. Phys. Med. Rehabil. 49(5), 269-275 (1968).
25. Weiner WJ, Singer C. Parkinson's disease and nonpharmacologic treatment programs. J. Am. Geriatr. Soc. 37, 359-363 (1989).
26. Oxtoby M. Parkinson's Disease People and their Social Needs. Parkinson's Disease Society, London, UK (1982).
27. Baker K, Ramig LO, Luschei E, Smith M. Thyroarytenoid muscle activity associated with hypophonia in Parkinson disease and aging. Neurology 51(6), 1592-1598 (1998). • Documents decreased laryngeal muscle activity (thyroarytenoid muscle) in people with Parkinson's disease (PD) as compared with healthy age-matched peers. This reduced muscle activation may be one factor underlying soft, monotone voice in people with PD.
28. Recent Advances in Clinical Dysarthria. Beukelman DR (Ed.) College-Hill Press, Boston, MA, USA. (1989).
29. Leanderson R, Meyerson BA, Persson A. Effect of L-dopa on speech in parkinsonism an EMG study of labial articulatory function. J. Neurol. Neurosurg. Psychiatr. 43, 679-681 (1971).
30. Leanderson R, Meyerson BA, Persson A. Lip muscle function in parkinsonian dysarthria. Acta. Otolaryngol. 74, 350-357 (1972).
31. Moore CA, Scudder RR. Coordination of jaw muscle activity in parkinsonian movement: description and response to traditional treatment. In: Recent Advances in Clinical Dysarthria. Yorkston KM, Beukelman DR (Eds). College-Hill Press, Boston, MA, USA. 147-163 (1989).
32. Yorkston KM. Treatment efficacy: dysarthria. J. Speech Hear. Res. 39, S46-S57 (1996).
33. Yorkston KM, Miller RM, Strand EA. Management of Speech and Swallowing in Degenerative Diseases. Communication Skill Builders, Tucson, AZ, USA (1997).
34. Ackermann H, Ziegler W. Articulatory deficits in parkinsonian dysarthria. J. Neurol. Neurosurg. Psychiatr. 54, 1093-1098 (1991).
35. Ackermann H, Konczak J, Hertrich I. The temporal control of repetitive articulatory movements in Parkinson's disease. Brain Lang. 56, 312-319 (1997).
36. Estenne M, Hubert M, Troyer AD. Respiratory-muscle involvement in Parkinson's disease. N. Engl. J. Med. 311, 1516-1517 (1984).
37. Hanson WR, Metter EJ. DAF Speech rate modification in Parkinson's disease: a report of two cases. In: Clinical Dysarthria. Berry WR. (Ed.). College-Hill Press, San Diego, CA, USA (1983).
38. Hoodin RB, Gilbert HR. Nasal airflows in parkinsonian speakers. J. Commun. Disord. 22, 169-180 (1989).
39. Hoodin RB, Gilbert HR. Parkinsonian dysarthria: an aerodynamic and perceptual description of velopharyngeal closure for speech. Folia Phoniatr. 41, 249-258 (1989).
40. Berardelli A, Rothwell JC, Thompson PD, Hallett M. Pathophysiology of bradykinesia in Parkinson's disease. Brain 124, 2131-2146 (2001).
41. Desmurget M, Grafton ST, Vindras P, Grea H, Turner RS. The basal ganglia network mediates the planning of movement amplitude. Eur. J. Neurosci. 19, 2871-2880 (2004).
42. Turner RS, Anderson ME. Pallidal discharge related to the kinematics of reaching movements in two dimensions. J. Neurophysiol. 77, 1051-1074 (1997).
43. Ho AK, Iansek R, Bradshaw JL. Regulations of parkinsonian speech volume: the effect of interlocuter distance. J. Neurol. Neurosurg. Psychiatr. 67(2), 199-202 (1999).
44. Ho AK, Bradshaw JL, Iansek T. Volume perception in parkinsonian speech. Mov. Disord. 15, 1125-1131 (2000).
45. Sapir S, Ramig L, Hoyt P, O'Brien C, Hoehn M. Phonatory-respiratory effort (LSVT® ) vs respiratory effort treatment for hypokinetic dysarthria: comparing speech loudness and quality before and 12 months after treatment. Folia Phoniatr. 54, 296-303 (2002).
46. Ho AK, Bradshaw JL, Iansek R, Alfredson R. Speech volume regulation in Parkinson's disease: effects of implicit cues and explicit instructions. Neuropsychologia 37, 1453-1460 (1999).
47. Georgiou N, Iansek R, Bradshaw JL, Phillips JG, Mattingley JB, Bradshaw JA. An evaluation of the role of internal cues in the pathogenesis of parkinsonian hypokinesia. Brain 116, 1575-1587 (1993).
48. Darley FL, Aronson AE, Brown JR. Clusters of deviant speech dimensions in the dysarthrias. J. Speech Hear. Res. 12, 462-469 (1969).
49. Darley FL, Aronson A, Brown J. Differential diagnostic patterns of dysarthria. J. Speech Hear. Res. 12, 246-269 (1969).
50. Darley FL, Aronson AE, Brown JR. Motor Speech Disorders. WB Saunders, PA, USA (1975).
51. Canter GJ. Speech characteristics of people with Parkinson's disease: I. Intensity, pitch and duration. J. Speech Hear. Disord. 28, 221-229 (1963).
52. Canter GJ. Speech characteristics of people with Parkinson's disease: III. Articulation, diadochokinesis and overall speech adequacy. J. Speech Hear. Disord. 30, 217-224 (1965).
53. Canter GJ. Speech characteristics of people with Parkinson's disease: II. Physiological support for speech. J. Speech Hear. Disord. 30, 44-49 (1965).
54. Ludlow CL, Bassich CJ. Relationships between perceptual ratings and acoustic measures of hypokinetic speech. In: Dysarthria of Speech: Physiology-Acoustics-Linguistics-Management. McNeil MR, Rosenbek JC, Aronson AE (Eds). College-Hill Press, San Diego, CA, USA. 163-196 (1983).
55. Metter EJ, Hanson WR. Clinical and acoustical variability in hypokinetic dysarthria. J. Commun. Disord. 19, 347-366 (1986).
56. Ho AK, Iansek R, Bradshaw JL. Motor instability in parkinsonian speech intensity. Neuropsychiatr. Neuropsychol. Behav. Neurol. 14, 109-116 (2001).
57. rd Annual Meeting. Seattle, WA, USA (1995).
58. Logemann J, Fisher H, Boshes B, Blonsky E. Frequency and concurrence of vocal tract dysfunctions in the speech of a large sample of Parkinson patients. J. Speech Hear. Disord. 43, 47-57 (1978).
59. Sapir S, Spielman J, Ramig L, Story B, Fox C. Effects of intensive voice treatment (LSVT® ) on vowel articulation in dysarthric individuals with idiopathic Parkinson's disease: acoustic and perceptual findings. J. Speech Lang. Hear. Res. 50, 899-912 (2007).
60. Uziel A, Bohe M, Cadilhac J, Passouant P. Les troubles de la voix et de la parole dans les syndromes parkinson'siens. Folia Phoniatr. 27(3), 166-176 (1975).
61. Weismer G. Articulatory characteristics of Parkinsonian dysarthria: segmental and phrase-level timing, spirantization and glottal-supraglottal coordination. In: The Dysarthrias: Physiology, Acoustics, Perception and Management. McNeil MR, Rosenbeck J, Aronson AE. (Eds). College Hill Press, San Diego, CA, USA. 101-130 (1984).
62. Perez K, Ramig LO, Smith M, Dromey C. The parkinson larynx: tremor and videostroboscopic findings. J. Voice 10, 354-361 (1996).
63. Smith M, Ramig LO, Dromey C, Perez K, Samandari R. Intensive voice treatment in Parkinson's disease: laryngostroboscopic findings. J. Voice 9, 453-459(1995). • Compared videostroboscopic ratings of vocal folds in individuals with PD following two forms of high effort, intensive treatment: Lee Silverman Voice Treatment (LSVT) and respiratory treatment. Only after LSVT did patients have improvements in vocal fold closure.
64. Solomon N, Hixon TJ. Speech breathing in Parkinson's disease. J. Speech Hear. Res. 36, 294-310 (1993).
65. Gallena S, Smith PJ, Zeffiro T, Ludlow CL. Effects of levodopa on laryngeal muscle activity for voice onset and offset in Parkinson disease. J. Speech Lang Hear Res. 44, 1284-1299 (2001).
66. Vincken W, Gauthier SG, Dollfuss RE, Hanson RE, Parauay CM, Cosio MG. Involvement of upper-airway muscles in extrapyramidal disorders, a cause of airflow limitation. N. Engl. J. Med. 7(311), 438-442 (1984).
67. Caligiuri M, Abbs JH. Response properties of the perioral reflex in Parkinson's disease. Exp. Neurol. 98, 563-572 (1987).
68. Hirose H. Pathophysiology of motor speech disorders (dysarthria). Folia Phoniat. (Basel) 38, 61-88 (1986).
69. Leanderson R, Persson A, Ohman S. Electromyographic studies of the function of the facial muscles in dysarthria. Acta Otolaryngol. Suppl. 263, 89-94 (1970).
70. Rosen K, Kent RD, Duffy JR. Task-based profile of vocal intensity decline in Parkinson's disease. Folia Phoniatr. Logop. 57, 28-37(2005).
71. Sapir S, Pawlas AA, Ramig LO et al. Voice and speech abnormalities in Parkinson disease: relation to severity of motor impairment, duration of disease, medication, depression, gender, and age. J. Med. Speech Lang. Pathol. 9, 213-226 (2001).
72. Goberman A. Correlation between acoustic speech characteristics and non-speech motor performance in Parkinson disease. Med. Sci. Monit. 11, CR109-CR116 (2005).
73. Trail M, Fox C, Ramig LO, Sapir S, Howard J, Lai EC. Speech treatment for Parkinson's disease. NeuroRehabilitation 20, 205-221 (2005).
74. Diamond SG, Schneider JS, Markham CH. Oral sensorimotor defects in people with Parkinson's disease. Adv. Neurol. 45, 335-338 (1987).
75. Schneider JS, Diamond SG, Markham CH. Deficits in orofacial sensorimotor function in Parkinson's disease. Ann. Neurol. 19, 275-282 (1986).
76. Basal Ganglia and Behavior: Sensory Aspects of Motor Functioning. Schneider JS, Lidsky TI (Eds). Hans Huber, Toronto, Canada (1987).
77. Graber S, Hertrich I, Daum I, Spieker S, Ackermann H. Speech perception deficits in Parkinson's disease: underestimation of time intervals compromises identification of durational phonetic contrasts. Brain Lang. 82, 65-74 (2002).
78. Solomon NP, Robin DA, Lorell DM, Rodnitzky RL, Luschei ES. Tongue function testing in Parkinson's disease: indicators of fatigue. In: Motor Speech Disorders: Advances in Assessment and Treatment. Till JA, Yorkston KM, Beukelman R. (Eds). Paul H. Brooks, Baltimore, MD, USA 147-160 (1994).
79. Fox CM, Morrison CE, Ramig LO, Sapir S. Current perspectives on the Lee Silverman Voice Treatment (LSVT) for people with idiopathic Parkinson's disease. Am. J. Speech. Lang. Pathol. 11, 111-123 (2002). •• Reviews the treatment efficacy data on LSVT and provides the motor, sensory and neuropsychological bases underlying this treatment.
80. Demirci M, Grill S, McShane L, Hallett M. A mismatch between kinesthetic and visual perception in Parkinson's disease. Ann. Neurol. 41, 781-788 (1997).
81. Jobst EE, Melnick ME, Byl NN, Dowling GA, Aminoff MJ. Sensory perception in Parkinson's disease. Arch. Neurol. 54, 450-454 (1997).
82. Klockgether T, Borutta M, Rapp H, Spieder S, Dichgans J. A defect of kinesthesia in Parkinson's disease. Brain 120, 460-465 (1997).
83. Rickards C, Cody FW. Proprioceptive control of wrist movements in Parkinson's disease. Brain 120, 977-990 (1997).
84. Oliveira RM, Gurd JM, Nixon P, Marshall JC, Passingham RE. Micrographia in Parkinson's disease: the effect of providing external cues. J. Neurol. Neurosurg. Psychiatr. 63(4), 429-433 (1997).
85. Schultz GM, Peterson T, Sapienza CM, Greer M, Friedman W. Voice and speech characteristics of persons with Parkinson's disease pre- and post-pallidotomy surgery: preliminary findings. J. Speech Hear. Res. 42, 1176-1194 (1999).
86. Schultz GM, Grant MK. Effects of speech therapy and pharmacologic and surgical treatments on voice and speech in Parkinson's disease: a review of the literature. J. Commun. Disord. 33, 59-88 (2000). • Reviews the impact of medical and speech treatments on speech and voice in PD. The authors conclude that intensive voice treatment (LSVT) in combination with pharmacological treatment generates the only significant improvement in speech and voice. Pharmacological and surgical treatments alone have limited effects on speech and voice in PD.
87. Pinto S, Ozsancak C, Tripoliti E, Thobois S, Limousin-Dowsey P, Auzou P. Treatments for dysarthria in Parkinson's disease. Lancet Neurol. 3, 547-556 (2004).
88. No authors listed. Speech therapy in Parkinson's disease. Mov. Disord. 17(4), S163-S166 (2002).
89. Yorkston KM, Spencer KA, Duffy JR. Behavioral management of respiratory/ phonatory dysfunction from dysarthria: a systematic review of the evidence. J. Med. Speech Lang. Pathol. 11, xiii-xxxviii (2003).
90. Sapir S, Ramig L, Fox C. The Lee Silverman Voice Treatment [LSVT® ] for voice, speech, and other orofacial disorders in people with Parkinson's disease. Future Neurol. 1, 563-570 (2006).
91. Radad K, Gille G, Rausch W. Short review on dopamine agonists: insight into clinical and research studies relevant to Parkinson's disease. Pharmacol. Rep. 57, 701-712 (2005).
92. De Letter M, Santens P, Van Borsel J. The effects of levodopa on word intelligibility in Parkinson's disease. J. Commun. Disord. 38, 187-196 (2005).
93. Goberman A, Coelho C, Robb M. Phonatory characteristics of parkinsonian speech before and after morning medication: the ON and OFF states. J. Commun. Disord. 35, 217-239 (2002).
94. Sanabria J, Ruiz PG, Gutierrez R et al. The effect of levodopa on vocal function in Parkinson's disease. Clin. Neuropharmacol. 24, 99-102 (2001).
95. Cahill L, Murdoch BE, Theodoros DG, Triggs EJ, Charles BG, Yao AA. Effect of oral levodopa treatment on articulatory function in Parkinson's disease: preliminary results. Motor Control 2, 161-172 (1998).
96. Jiang J, Lin E, Wang J, Hanson DG. Glottographic measures before and after levodopa treatment in Parkinson's disease. Laryngoscope 109, 1287-1294 (1999).
97. Biary N, Pimental PA, Langenberg PW. A double-blind trial of clonazepan in the treatment of parkinsonian dysarthria. Neurology 38(2), 255-258 (1988).
98. Krack P, Batir A, VanBiercom N et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N. Engl. J. Med. 20, 1925-1934 (2003).
99. Witt K, Pulkowski U, Herzog J et al. Deep brain stimulation of the subthalamic nucleus improves cognitive flexibility but impairs response inhibition in Parkinson disease. Arch. Neurol. 61, 697-700 (2004).
100. D'Alatri L, Paludetti G, Contarino MF, Galla S, Marchese MR, Bentivoglio AR. Effects of bilateral subthalamic nucleus stimulation and medication on parkinsonian speech impairment. J. Voice (2007) (Epub ahead of print).
101. Klostermann F, Ehlen F, Vesper J et al. Effects of subthalamic deep brain stimulation on dysarthrophonia in Parkinson's disease. J. Neurol. Neurosurg. Psychiatr. (2007) (In Press).
102. Törnqvist AL, Schalén L, Rehncrona S. Effects of different electrical parameter settings on the intelligibility of speech in patients with Parkinson's disease treated with subthalamic deep brain stimulation. Mov. Disord. 20, 416-423 (2005).
103. Deane KHO, Whurr R, Playford ED, Ben-Shlomo Y, Clarke CE. Speech and language therapy for dysarthria in Parkinson's disease: a comparison of techniques (Cochrane Review). The Cochrane Library (Issue 2). John Wiley & Sons, Ltd., Chichester, UK (2004).
104. Deane KHO, Whurr R, Playford ED, Ben-Shlomo Y, Clarke CE. Speech and language therapy versus placebo or no intervention for dysarthria in Parkinson's disease. The Cochrane Library (Issue 2). John Wiley & Sons, Ltd., Chichester, UK (2004).
105. NICE, National Collaborating Centre for Chronic Conditions. Parkinson's disease: national clinical guideline for diagnosis and management in primary and secondary care. Royal College of Physicians, London, UK (2006).
106. Suchowersky O, Gronseth G, Perlmutter J, Reich S, Zesiewicz T. Weiner WJ. Practice parameter: neuroprotective strategies and alternative therapies for Parkinson disease. Neurology 66, 976-982 (2006).
107. Ramig LO, Countryman S, O'Brien C, Hoehn M, Thompson L. Intensive speech treatment for people with Parkinson's disease: short and long term comparison of two techniques. Neurology 47, 1496-1504 (1996).
108. Johnson J, Pring T. Speech therapy and Parkinson's disease: a review and further data. Br. J. Disord. Commun. 125, 183-194 (1990).
109. Scott S, Caird FL. Speech therapy for Parkinson's disease. J. Neurol. Neurosurg. Psychiatr. 46, 140-144 (1983).
110. Ramig LO, Sapir S, Countryman S et al. Intensive voice treatment (LSVT® ) for people with Parkinson's disease: a 2 year follow-up. J. Neurol. Neurosurg. Psychiatr. 71, 493-498 (2001). •• The randomized control trial (RCT) is considered as level 1 evidence for effective speech treatment for PD. The short and long-term (2 year) impact of two forms of speech treatment (LSVT and respiratory) on speech and voice in PD were compared. Only patients who received LSVT had statistically significant increases in sound pressure level post-treatment (vs pretreatment) that were maintained 2 years after 1 month of treatment. Patients who received respiratory treatment had no significant increases in sound pressure level and 2 years after treatment were statistically significantly softer than the patients who received LSVT.
111. Ramig L, Sapir S, Fox C, Countryman S. Changes in vocal intensity following intensive voice treatment (LSVT® ) in people with Parkinson disease: a comparison with untreated people and with normal age-matched controls. Mov. Disord. 16, 79-83 (2001). •• This RCT evaluates the short- and long-term (6 months) impact of LSVT on speech and voice in PD when compared with untreated PD and healthy control groups. Only patients who received LSVT had a statistically significant on post treatment sound pressure level which was maintained 6 months after treatment.
112. Montgomery EB, Turkstra LS. Evidence-based practice: let's be reasonable. J. Med. Speech Lang. Pathol. 11(2), ix-xii (2003).
113. Yorkston KM, Hakel, M, Beukelman DR, Fager S. Evidence for effectiveness of treatment of loudness, rate, or prosody in dysarthria: a systematic review. J. Med. Speech Lang. Pathol. 15(2), xi-xxxvi (2007).
114. Robey RR, Schultz MC. A model for conducting clinical-outcome research: an adaptation of the standard protocol for use in aphasiology. Aphasiology. 12, 787-810 (1998).
115. Albin RL, Young AB, Penny JB. The functional anatomy of basal ganglia disorders. Trends Neurosci. 12, 366-375 (1989).
116. Barbeau A, Sourkes TL, Murphy CF. Les catecholamines de la maladie de Parkinson's. In: Monoamines et Systeme Nerveux Central. Ajuriaguerra J. (Ed.). George, Geneve, Switzerland. 247-262 (1962).
117. Penny JB, Young AB. Speculations on the functional anatomy of basal ganglia disorders. Annu. Rev. Neurosci. 6, 73-94 (1983).
118. Berardelli A, Dick JP, Rothwell JC, Day BL, Marsden CD. Scaling of the size of the first agonist EMG burst during rapid wrist movements in people with Parkinson's disease. J. Neurol. Neurosurg. Psychiatr. 49(11), 1273-1279 (1986).
119. Demirci M, Grill S, McShane L, Hallet M. Impairment of kinesthesia in Parkinson's disease. Neurology 45, A218 (1995).
120. Stelmach GE. Basal ganglia impairment and force control. In: Tutorial in Motor Neuroscience. Requin J, Stelmach GE. (Eds). Kluwer Academic Publishers, The Netherlands. 147-158 (1991).
121. Fisher B, Petzinger G, Nixon K et al. Exercise-induced behavioral recovery and neuroplasticity in the 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-lesioned mouse basal ganglia. J. Neurosci. Res. 77, 378-390 (2004).
122. Liepert J, Miltner W, Bauder H et al. Motor cortex plasticity during constraint-induced movement therapy in stroke patients. Neurosci. Lett. 250, 5-8 (1998).
123. Kleim J, Jones T, Schallert T. Motor enrichment and the induction of plasticity before or after brain injury, Neurochem. Res. 11, 1757-1769 (2003).
124. Liotti M, Ramig LO, Vogel D et al. Hypophonia in Parkinson's disease. Neural correlates of voice treatment revealed by PET. Neurology 60, 432-440 (2003). •• This paper documents changes in neural functioning through PET imaging in patients with PD following LSVT.
125. Fox C, Ramig L, Ciucci M, Sapir S, McFarland D, Farley B. The science and practice of LSVT/LOUD: neural plasticity-principled approach to treating individuals with Parkinson disease and other neurological disorders. Semin. Speech Lang. 27(4), 283-299 (2006)
126. Taub E. Harnessing brain plasticity through behavioral techniques to produce new treatments in neurorehabilitation. Am. Psychol. 59(8), 692-704 (2004).
127. Fisher B, Yip J. Physical therapy for individuals with Parkinson's disease: a paradigm shift. Parkinson Report XVI(2), 10-13 (2005).
128. Dromey C, Ramig L. Intentional changes in sound pressure level and rate: their impact on measures of respiration, phonation, and articulation. J. Speech Lang. Hear. Res. 41, 1003-1018 (1998).
129. Allen G. Segmental timing control in speech production. J. Phon. 1, 219-237 (1973).
130. Gandour J, Dechongkit S, Ponglorpisit S, Khunadorn F. Speech timing at the sentence level in Thai after unilateral brain damage. Brain Lang. 46, 419-438 (1994).
131. McClean MD, Tasko SM. Association of orofacial with laryngeal and respiratory motor output during speech. Exp. Brain Res. 146, 481-489 (2002).
132. Ackermann H, Wildgruber D, Daum I, Grodd W. Does the cerebellum contribute to cognitive aspects of speech production? A functional magnetic resonance imaging (fMRI) study in humans. Neurosci. Lett. 247, 187-190 (1998).
133. Hirano S, Kojima H, Naito Y et al. Cortical speech processing mechanisms while vocalizing visually presented languages. Neuroreport. 8, 363-367 (1996).
134. Jurgens U, Kirzinger A, von Cramon D. The effects of deep-reaching lesions in the cortical face area on phonation. A combined case report and experimental monkey study. Cortex 18, 125-130 (1982).
135. Kitchen DM, Cheney DL, Seyfarth RM. Male chacma baboons (Papio hamadryas ursinus) discriminate loud call contests between rivals of different relative ranks. Anim. Cogn 8, 1-6 (2005).
136. Leinonen L, Laakso ML, Carlson S, Linnankoski I. Shared means and meanings in vocal expression of man and macaque. Logoped. Phoniatr. Vocol. 28, 53-61 (2003).
137. Tecumseh W. The phonetic potential of nonhuman vocal tracts: comparative cineradiographic observations of vocalizing animals. Phonetica 57, 205-218 (2000).
138. th Annual Meeting of the Organization for Human Brain Mapping. Toronto, Ontario, Canada, 12-16 June 2005.
139. Dobkins BH. Confounders in rehabilitation trials of task-oriented training: lessons from the designs of the EXCITE and SCILT multicenter trials. Neurorehabil. Neural Repair. 21(1), 3-13 (2007).
140. Duncan S. Preliminary data on effects of behavioral and levadopa therapies of speech-accompanying gesture in Parkinson's disease. Presented at: ICSLP Meeting. Denver, CO, USA, 16-20 September 2002.
141. El Sharkawi A, Ramig LO, Logemann JA, et al. Swallowing and voice effects of Lee Silverman Voice Treatment (LSVT® ): a pilot study. J. Neurol. Neurosurg. Psychiatr. 71, 31-36 (2002).
142. Ramig LO, Bonitati C, Lemke J, Horii Y. Voice treatment for people with Parkinson disease: development of an approach and preliminary efficacy data. J. Med. Speech Lang. Pathol. 2, 191-209 (1994).
143. Ramig LO, Dromey C, Johnson A, Scherer R. The effects of phonatory, respiratory and articulatory effect treatment on speech and voice in Parkinson's disease. Presented at: Motor Speech Conference, Sedona, AZ, April 1994.
144. Farley BF, Koshland CF, Prior MM. Learning big decreases bradykinesia in the upper and lower limbs in people with Parkinson's disease. Presented at: Annual Society for Neuroscience Meeting. San Diego, CA, USA, 23-27 October 2004.
145. th International Congress of Parkinson's Disease and Movement Disorders. New Orleans, LA, USA, 5-8 March 2005.
146. Fox CM, Farley BG, Ramig LO, McFarland D. An integrated rehabilitation approach to Parkinson's disease: learning big and loud. Mov. Disord. 20(10), S127 (2005).
147. Fox CM, Farley BG, Ramig LO, McFarland D. An integrated speech and physical therapy approach for Parkinson's disease: training big and loud. Mov. Disord. 22(16), S98-S99 (2007).
148. Ramig L, Countryman S, Thompson L, Horii Y. Comparison of two forms of intensive speech treatment for Parkinson disease. J. Speech Hear. Res. 38, 1232-1251 (1995).
149. Ciucci MR, Ma TS, Fox CM, Kane J, Ramig L, Schallert T. Qualitative changes in ultrasonic vocalization in rats after unilateral dopamine depletion or haloperidol: a preliminary study. Behav. Brain Res. 182, 284-289 (2007).
150. Taub E, Lum PS, Hardin P, Mark BW, Uswatte G. AutoCITE: automated delivery of CI therapy with reduced effort by therapists. Stroke. 36, 1301-1304 (2005).
151. Halpern AE, Matos C, Ramig LO, Petska J, Spielman J. LSVTC - a PDA supported speech treatment for Parkinson's disease. Presented at: Annual American Speech-Language-Hearing Association Meeting. Philadelphia, PA, USA, 17-22 July 2004.
152. th International Congress of Parkinson's Disease and Movement Disorders. New Orleans, LA, USA 5-8 March 2005.
153. Ramig LO, Pawlas A, Countryman S. The Lee Silverman Voice Treatment (LSVT): A Practical Guide to Treating the Voice and Speech Disorders in Parkinson Disease. National Center for Voice and Speech, IA, USA (1995).